

Best Available Copy



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 410 655 A1**

12

## EUROPEAN PATENT APPLICATION

21 Application number: **90307952.3**

51 Int. Cl.<sup>5</sup>: **C12N 15/72, C12N 1/21**

22 Date of filing: **20.07.90**

30 Priority: **27.07.89 US 386821**

43 Date of publication of application:  
**30.01.91 Bulletin 91/05**

64 Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

71 Applicant: **Mycogen Corporation**  
**5451 Oberlin Drive**  
**San Diego, CA 92121(US)**

72 Inventor: **Wilcox, Edward R.**  
**5 Lopa Court**  
**North Potomac, Maryland 20878(US)**

74 Representative: **Perry, Robert Edward et al**  
**GILL JENNINGS & EVERY 53-64 Chancery**  
**Laneane**  
**London WC2A 1HN(GB)**

54 Improved control of expression of heterologous genes from lac operated promoters.

57 The invention is a process for controlling the expression of heterologous genes from lac -operated promoters by removing the CAP binding site and lac promoter from the lac operon. Illustrated is the fusion of the lacZ, Y, and A genes of the lac operon to the 3' end of the lacI structural gene. This elimination of the natural regulatory elements of the lac operon results, advantageously, in the production of lac operon gene products in a constitutive mode from the lacI promoter.

EP 0 410 655 A1

## IMPROVED CONTROL OF EXPRESSION OF HETEROLOGOUS GENES FROM LAC OPERATED PROMOTERS

Background of the Invention

The lactose ( lac ) operon consists of three protein products under the control of a lac promoter-operator. These gene products are  $\beta$ -galactosidase ( Z ) permease ( Y ), and thiogalactoside transacetylase ( A ). The protein product of the lacI transcript (repressor), an independent gene product, interacts with the operator of the lac operon and keeps synthesis off until allolactose (1,6-0- $\beta$ -D-galactopyranosyl-D-glucose), a product of the  $\beta$ -galactosidase reaction, accumulates in the cell and binds to the repressor. The allolactose repressor complex has a changed conformation, allowing the repressor to be displaced from the operator. RNA transcription then begins from the lac promoter (Beckwith, J. [1987] In *Escherichia coli* and *Salmonella typhimurium* Cellular and Molecular Biology . Vol. 2, Neidhardt, F.C., Editor in Chief, American Society for Microbiology, Washington, D.C.).

A few molecules of the lac operon transcript are present in *E. coli* , even in the absence of lactose. Hence, permease and  $\beta$ -galactosidase are always present, at least at a low level. Allolactose, the natural inducer of the operon, is made in the cell when lactose (1,4-0- $\beta$ -D-galactopyranosyl-D-glucose) enters the cell by the permease reaction and is converted through transgalactosidation by  $\beta$ -galactosidase into allolactose (Freifelder, D., [1987] *Molecular Biology* . Jones and Bartlett Publishers, Inc., Portola Valley, CA; Beckwith, *supra* ). It was calculated that greater than 20% of the lactose acted upon by  $\beta$ -galactosidase is converted to allolactose (Jobe, A., Bourgeois, S., [1972] *J. Mol. Biol.* 69 :397-408). The majority of the remaining lactose is converted to glucose and galactose. Allolactose is a better substrate for  $\beta$ -galactosidase than lactose (Jobe and Bourgeois, *supra* , and is itself rapidly converted to glucose and galactose.

Another control element of the lac operon is catabolite repression. In the presence of glucose the cell is able to repress many operons. For example the lac operon is only transcribed at 2% of its maximum level in the presence of glucose (Beckwith, *supra* ).

When several  $\beta$ -galactosides were compared for their ability to induce the lac operon *in vivo* , lactose was found to act as a very poor effector molecule. The synthetic non-metabolized  $\beta$ -galactoside, isopropyl- $\beta$ -D-thiogalactoside (IPTG), was found to induce the lactose operon 5 times better than lactose (Monod, J., G. Cohen-Bazire and M. Cohn [1951] *Biochim. Biophys. Acta.* 7 :585-599). Yet, allolactose itself is as good an inducer of the operon as IPTG (Muller-Hill, B., H.V. Rickenberg and K Wallenfels [1964] *J. Mol. Biol.* 10 :303-318; Jobe and Bourgeois, *supra* ).

Given the efficiency of lactose conversion to allolactose, one might expect lactose to work very well as an inducer of the lac operon. However, prior to the present disclosure, this has never occurred in practice (Monod et al., *supra* ).

The current way to control the expression of heterologous genes from the lac promoter or lac consensus promoters such as tac (Rezinkoff, W.S. and W.R. McClure [1986] *Maximizing Gene Expression* . W. Reznikoff and L. Gold, eds., Butterworth Publishers, Stoneham, MA) is to have enough lac repressor present in the cell, so that transcription from the lac promoter is off until IPTG or another proper inducing  $\beta$ -galactoside is added to the cell. Although IPTG is the current inducer of choice, it is expensive and has been labeled a potential carcinogen. Thus, there is a need to replace IPTG in commercial systems where control of the expression of heterologous genes from lac operated promoters is used.

Brief Summary of the Invention

The subject invention concerns an improved method for controlling the expression of heterologous genes from lac operated promoters. Specifically, the subject invention concerns a method for controlling the expression of heterologous genes from lac operated promoters which comprises removing the CAP binding site and lac promoter/operator from the lac operon. The subject invention is exemplified herein by use of a novel recombinant DNA construct comprising the lacZ , Y and A genes of the lac operon, to control the expression of heterologous genes from lac operated promoters. The lacZ , Y , and A genes of the lac operon were fused to the 3' end of the lacI structural gene, thereby eliminating all of the natural regulatory elements of the lac operon. By doing this, lac operon gene products are produced in a constitutive mode from the lacI promoter and are not responsive to catabolite repression or to allolactose induction. When lactose is added, the constitutively synthesized  $\beta$ -galactosidase converts as much as 20% to allolactose.

which in turn derepresses the lac promoter and any associated heterologous gene. As long as the allolactose concentration in the cell is above  $10^{-5}$  M the lac promoter provides high expression of the protein of interest. The complete DNA sequence of the transcriptional fusion of the lacI gene to the lacZ, Y, and A genes of the subject invention is as shown in Table 1.

5 The novel lacIZYA operon (Table 1) can be inserted in any plasmid, or it can be inserted into any microbial chromosome to improve control of heterologous gene expression from a lac operated promoter (as long as a promoter is present to drive lacIZYA transcription). It will be apparent to a person skilled in the art that other constructs can be used to fuse the genes.

The lac operator, which has very high affinity for the lacI repressor ( $K_{DNA} = 2.5 \times 10^{13} \text{ M}^{-1}$ ), is a  
 10 sequence 21 b.p. long as follows; AATTGTGAGCGGATAACAATT (Barkley, M.D. and S. Bourgeois [1978] In The Operon Miller, J.H. and W.S. Reznikoff, eds. Cold Spring Harbor). Many mutations within the lac operator exist which have higher or lower affinities to the lacI repressor (Barkley and Bourgeois, *supra*; Sadler, J.R. et al. [1983] Proc. Natl. Acad. Sci. USA 80 :6785-6789; Simons, A. et al. [1984] Proc. Natl. Acad. Sci. USA 81 :1624-1628). Many mutations exist within the lacI repressor that allow for greater affinity  
 15 to the U operator with no significant effect on derepression (Barkley and Bourgeois, *supra*). Using any of the many different combinations of lac operator and lacI repressor, the control of heterologous gene expression is apparent to a person skilled in the art. Many different promoters (eukaryotic as well as prokaryotic) have been placed under lac operator regulation (Yansura, D.G. and D.J. Henner [1984] Proc. Natl. Acad. Sci. USA 81 :439-443; Herrin Jr., G.L and G.N. Bennett [1984] Gene 32 :349-356; Deuschle, U., et al. [1986] Proc. Natl. Acad. Sci. USA 83 :4134-4137; Hu, M.C.-T. and N. Davidson [1988] Gene 62 :301-314; Figge, J., et al. [1988] Cell 52 :713-722). The subject invention is designed to improve lactose  
 20 induction from such lac operated promoters.

This invention enables cells to make enough lacZ and Y protein to efficiently take up lactose and convert it to glucose and galactose, as well as to the true lac inducer, allolactose. In addition, the invention  
 25 enables the cell to synthesize enough repressor (lacI protein) to bind to the lac operator upstream from a heterologous gene, and keep heterologous gene expression off in the absence of inducer. With excess lactose present in the medium, the cell can accumulate sufficient concentrations of allolactose for efficient derepression of the lac operator.

30

### Brief Description of the Drawings

Figure 1 - pMYC 2005, LacI and Z operon fusion

35 A synthetic fragment of DNA was cloned into pUC18 to replace the normal sequence found at Hin d III-403 to Hae II-524. This synthetic sequence removes the lac promoter and operator sequences and replaces them with a Shine-Dalgarno site.

Figure 2 - pMYC 2101, construction of the lacIZYA operon

40 Three fragments of DNA were ligated and then introduced by transformation into MC1061 (Casadaban, M. and S. Cohen [1980] J. Mol. Biol. 138 :179-207) to construct the plasmid pMYC2101. The first fragment came from pMYC2005 as a Hin d III-403 to Eae I-485 piece, the second fragment came from pMC9 as an Eco RI-1 to Eae I-1103 piece and the final fragment comes from pSKS107 as a 9889 bp Hin d III-31 to Eco RI-1 piece. Once constructed, the Eco RI and Sal I ends were converted to Bam HI and Bgl II ends, respectively, using oligonucleotide linkers, creating pMYC2101-B.

45 Figure 3 - pMYC467, a tac promoted toxin-containing plasmid

The tac promoted toxin gene found in pMYC436 (NRRL deposit no. B-18292) was cloned as a 4.5 Kbp Bam HI to Pst I fragment in the vector pTJS260. Not all the sequence of pTJS260 or of the 3' flanking sequences of the toxin genes are available, hence some restriction sites are approximated in Figures 3, 4, 5 and 6.

50 Figure 4 - pMYC471, a lactose inducible plasmid

The lacIZYA operon was cloned into the Bam HI site of pMYC467. The resulting plasmid, pMYC471, was then induced by transformation into MB101, a *P. fluorescens*.

Figure 5 - pMYC485, an alternate lactose inducible plasmid

55 A lacI <sup>Q</sup>ZYA operon was constructed by replacing lacI with lacI <sup>Q</sup> as a 638 bp Bam HI to Apa I fragment. The lacI <sup>Q</sup>ZYA operon was then cloned into the Bam HI site of pMYC467. The resulting plasmid, pMYC485, was tested in MB101 for lactose inducibility. The lacI <sup>Q</sup>ZYA operon is shown in Table 1 wherein base 16 is a T instead of a C as shown in the table.

Figure 6 - pMYC1611, a coleopteran toxin-lactose inducible plasmid

The plasmid pMYC471 was cut with Bam HI (at position 12103) and Kpn I (at position 7933) to remove the tac -promoted lepidopteran-active toxin and then both ends were filled in with T4 DNA polymerase, resulting in blunt termini. The tac promoted toxin gene disclosed in U.S. Patent 4,771,131, was inserted into the above DNA as a blunt-ended Sca I (of pBR322) to filled-in Hin dIII fragment (at the 3' end of the coleopteran-active sequence). The 5' end of the tac promoter had been previously inserted by blunt-end ligation into the Eco RI site of pBR322.

#### Detailed Disclosure of the Invention

Upon removal of the CAP binding site and lac promoter/operator from the lac operon, there is realized an improved control of expression of a heterologous gene. Exemplified herein is the insertion of a lacIZYA fusion construct into a plasmid containing a tac -promoted gene encoding a lepidopteran insect toxin. The plasmid (pMYC471) was then used to transform Pseudomonas fluorescens, which was designated Pseudomonas fluorescens MR471 (pMYC471).

One element of plasmid pMYC471 provides its host with constitutive levels of lac operon gene products. For this purpose, the operon could be fused to any of a variety of available constitutive promoters. In this instance, it was fused to the lacI promoter. In addition, a new construct containing a lacI<sup>q</sup> promoter, instead of the lacI promoter, was made (pMYC485). This new construct provides higher levels of the repressor as well as of lac operon gene products. The plasmid, pMYC485, functions like pMYC471.

As a demonstration that lactose inducibility is not dependent on the specific gene under tac promoter control, another gene encoding a coleopteran-active toxin was cloned into the pMYC471 vector replacing the lepidopteran-active toxin gene, resulting in pMYC1161. Pseudomonas fluorescens strain MB101 carrying this new plasmid also permits lactose induction of toxin expression. This will hold true for any gene under control of a lac operated promoter.

Another aspect of this fusion is that the lac operon is no longer regulated by the normal control elements associated with lactose. This means that synthesis of lac operon ZYA gene products in these constructs (pMYC471, pMYC485, and pMYC1161) is constitutive and occurs independently of the concentrations of lactose or glucose present in the cell. For example, in the presence or absence of IPTG or lactose, a new protein band corresponding to the mass of  $\beta$ -galactosidase is apparent on SDS-PAGE and the clones cleave X-gal, forming blue colonies under the same conditions.

For ease in construction, the lacA gene has been included on all the plasmids containing lacIZYA mentioned in this disclosure. The lacA gene product has no role (Freifelder, *supra*) in production of allolactose and can easily be removed from the lacIZYA operon. For example, there is a non-unique Afl II (CTTAAG) restriction enzyme site at the stop codon of the lacY gene. By using this Afl II restriction site, it is possible to remove the lacA gene. The lacIZY operon has the same lactose induction properties as those found in the lacIZYA operon.

The data of Table 2 demonstrate toxin production is regulated by lactose or IPTG. Although the amount of lactose used for induction is 10 to 20 fold higher than IPTG induction levels, the significantly reduced cost of lactose (\$7.00 per kilo, Sigma Chemical Co.) compared to IPTG (\$20,000 per kilo, Sigma Chemical Co.) make the former inducer highly economically advantageous. For maximum production levels the metabolized substrate, lactose, must be replenished during cell growth or the culture will decrease the synthesis of the tac -promoted gene.

#### Materials and Methods

Cloning and DNA manipulation techniques are described in Maniatis, T., E.F. Fritsch and J. Sambrook (1982) Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Publishers, Cold Spring Harbor, New York.

A plasmid containing the lac operon, pSKS107, was received from Dr. M. Casadaban at the University of Chicago (Shapira, S.K., J. Chou, F.V. Richaud and M.J. Casadaban [1983] Gene 25 :71-82). The sequence of the lac operon is published (Kalnins, A., K Otto, U. Ruther and B. Muller-Hill [1983] EMBO J. 2 :593-597; Hediger, M.A., D.F. Johnson, D.P. Nierlich and I. Zabin [1985] Proc. Nat. Acad. Sci. 82 :6414-6418). The lacI gene, on a 1.7KB Eco RI restriction fragment cloned into pBR322, is available from the ATCC, as pMC9, catalogue no. 37195, 37196 and 37197. The sequence of the lacI gene is also published (Farabaugh, P.J. [1978] Nature 274 :765-769). The broad host range vector, pMMB22, was received from Dr. M.

Bagdasarian (Bagdasarian, M.M., E. Amann, R. Lurz, B. Ruckert and M Bagdasarian [1983] Gene 26 :273-282). A Hin dIII fragment of pMMB22, containing the lacI<sup>q</sup> gene, was relinked to Bam HI. The sequence of the lacI<sup>q</sup> gene has also been published (Calos, M.P. [1978] Nature 274 :762-765). Analysis here is largely based on the published DNA sequences. Some of the critical portions of the constructs were confirmed by DNA sequencing, e.g., the lacI and lacI<sup>q</sup> promoters and the fusion region between the lacI transcriptional unit and the lac operon. The vector, pUC18, is available from a variety of sources, such as catalogue no. 27-4949-01 of Pharmacia Corporation. The broad host range vector, pTJS260, is available from Dr. D.R. Helinski at the University of California, San Diego, La Jolla CA 92093 (Schmidhauser, T.J. [1986] Ph.D Thesis, UCSD).

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

#### Example 1 - Fusions of the LacI Gene and Lac Operon.

Fusions of the lacI gene and lac operon were first carried out in pUC18. To do so, pUC18 was linearized with Hin dIII and then partially cut with Hae II. The DNA was resolved by electrophoresis on a 1.4% agarose gel. The 2402 bp band was eluted and ligated to a double-stranded synthetic DNA insert produced by  $\beta$ -cyanoester chemistry on an Applied Biosystems 380A oligonucleotide synthesizer. This sequence starts at BP 1073 of the lacI sequence (Farabaugh, P.J., supra) as seen in Table 1.

Hae II

Eae I

CC AAT ACG CAA ACC GCC TCT CCC CGC GCG TTG GCC GAT  
CGCGGG TTA TGC GTT TGG CGG AGA GGG GCG CGC AAC CGG CTA

Xho I

TCA TTA ATG CAA CTC GCA CGA CAG GTC TCG AGA CTG GAA AGC  
AGT AAT TAC GTT GAG CGT GCT GTC CAG AGC TCT GAC CTT TCG

lacI

lacZ

Stop

S/D

Start

Hind III

GGG CAG TGA GCGCTAGGAGGTAAGT ATG GAA  
CCC GTC ACT CGCGATCCTCCATTGAA TAC CTTTCGA

The above synthetic sequence removes the Pvu II site normally found at BP 1123 of lacI. A new XhoI site was inserted near the 3' end of the lacI gene (BP 1137). These changes were introduced for ease in identification of the new construct. No amino acid changes would occur as a result of the mutations introduced in making the base pair changes for the above two restriction sites. In this construct, the distance between the stop codon of lacI and the start codon of lacZ is 17 base pairs. This region contains a ribosome binding site (marked as S/D) such that a ribosome translating the lacI transcript will be able to continue synthesis of the lacZ gene product from the same transcript. A plasmid diagram of pMYC2005 is seen in Figure 1.

#### Example 2 - Confirmation of Sequence.

The synthetic portion of pMYC2005 was sequenced to validate its structure and was used in a three-piece ligation to tie the full lacI gene of pMC9 to the lac operon found in pSKS107 (Figure 2). After transformation, the lacI/Z fusion region was sequenced from a blue colony on an LB + X-gal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactosidase, a colorimetric substrate for the presence of  $\beta$ -galactosidase) plate. Those restriction sites that were examined yielded fragments of the predicted sized (Figure 2). The lacI

promoter region was also confirmed by sequence analysis.

### Example 3 - Cloning.

5

The Eco RI and Sal I ends of the lacIZYA construct (Figure 2) were respectively relinked to yield Bam HI and Bgl II restriction sites. The lacIZYA operon was cloned into the unique Bam HI site of pMYC467 (Figure 3) yielding pMYC471 (Figure 4). The plasmid, pMYC467, contains the tac promoted lepidopteran toxin gene of pMYC436 (a cry IA(c)-like toxin gene [NRRL deposit no. B-18292] Adang, M.J. et al. [1985] Gene 36 :289-300) cloned into the broad host range vector, pTJS260. pMYC471 was introduced by transformation into P. flourescens MB101 and the resulting clone was designated MR471. MR471 was tested for the key elements of the resident pMYC471 plasmid. A functional repressor is synthesized because in the absence of IPTG or lactose no significant amount of toxin is produced (Table 1). The cells are blue when plated on X-gal because a functional  $\beta$ -galactosidase is present. A functional permease and  $\beta$ -galactosidase are present because the cells are able to induce the tac promoter in the presence of lactose (Table 1).

10

The subject invention can be used with any heterologous gene to control its expression from lac operated promoters. The expression product (protein) can be isolated from the culture medium of the producing microbe by means known in the art for isolating such a product from microbial cultures. Alternatively, a product which remains intracellular can be used in the form of the microbe itself, for example, as a biological insecticide. See U.S. patents 4,695,455 and 4,695,462 for such uses.

15

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

55

T in lac I<sup>Q</sup>

1 GACACCATCG AATGGCGCAA AACCTTTCGC GGTATGGCAT GATAGCGCCC

start codon  
lac I

51 GGAAGAGAGT CAATTCAGGG TGGTGAATGT GAAACCAGTA ACGTTATACG

101 ATGTGCGAGA GTATGCCGGT GTCTCTTATC AGACCGTTTC CCGCGTGGTG

151 AACCAGGCCA GCCACGTTTC TGCGAAAACG CGGGAAAAAG TGGAAGCGGC

201 GATGGCGGAG CTGAATTACA TTCCCAACCG CGTGGCACA CAACTGGCGG

251 GCAAACAGTC GTTGCTGATT GCGCTTGCCA CCTCCAGTCT GGCCCTGCAC

301 GCGCCGTCGC AAATTGTCGC GCGGATTAA TCTCGCGCCG ATCAACTGGG

351 TGCCAGCGTG GTGGTGTCGA TGGTAGAACG AAGCGGCGTC GAAGCCTGTA

401 AAGCGGCGGT GCACAATCTT CTCGCGCAAC GCGTCAGTGG GCTGATCATT

451 AACTATCCGC TGGATGACCA GGATGCCATT GCTGTGGAAG CTGCCTGCAC

501 TAATGTTCCG GCGTTATTTT TTGATGTCTC TGACCAGACA CCCATCAACA

551 GTATTATTTT CTCCCATGAA GACGGTACGC GACTGGGCGT GGAGCATCTG

601 GTCGCATTGG GTCACCAGCA AATCGCGCTG TTAGCGGGCC CATTAAAGTC

651 TGTCTCGGCG CGTCTGCGTC TGGCTGGCTG GCATAAATAT CTCACTCGCA

701 ATCAAATTCA GCCGATAGCG GAACGGGAAG GCGACTGGAG TGCCATGTCC

751 GGTTTTCAAC AAACCATGCA AATGCTGAAT GAGGGCATCG TTCCCACTGG

801 GATGCTGGTT GCCAACGATC AGATGGCGCT GGGCGCAATG CGCGCCATTA

851 CCGAGTCCGG GCTGCGCGTT GGTGCGGATA TCTCGGTAGT GGGATACGAC

901 GATACCGAAG ACAGCTCATG TTATATCCCG CCGTCAACCA CCATCAAACA

951 GGATTTTCGC CTGCTGGGGC AAACCAGCGT GGACCGCTTG CTGCAACTCT

1001 CTCAGGGCCA GGCGGTGAAG GGCAATCAGC TGTGCCCCGT CTCACTGGTG

1051 AAAAGAAAAA CCACCCTGGC GC'CCAATACG CAAACCGCCT CTCCCCGCGC

Table 1 continued

5 1101 GTTGGCCGAT TCATTAATGC AACTCGCAGC ACAGGTCTCG AGACTGGAAA

stop codon                      start codon  
lac I                              lac Z                              (1)

1151 GCGGGCAGTG AGCGCTAGGA GGTAACCTAT GGAA'AGCTTG GCACTGGCCG

10 1201 TCGTTTTACA ACGTCGTGAC TGGGAAAACC CTGGCGTTAC CCAACTTAAT

1251 CGCCTTGACAG CACATCCCCC TTTCGCCAGC TGGCGTAATA GCGAAGAGGC

1301 CCGCACCGAT CGCCCTTCCC AACAGTTGCG CAGCCTGAAT GCGAATGGC

15 1351 GCTTTGCCTG GTTCCGSCA CCAGAAGCGG TGCCGGAAAG CTGGCTGGAG

1401 TGCGATCTTC CTGAGGCCGA TACTGTCGTC GTCCCCTCAA ACTGGCAGAT

1451 GCACGGTTAC GATGCGCCCA TCTACACCAA CGTAACCTAT CCCATTACG

20 1501 TCAATCCGCC GTTTGTTCCC ACGGAGAATC CGACGGGTTG TTA CTGCTC

1551 ACATTTAATG TTGATGAAAG CTGGCTACAG GAAGGCCAGA CGCGAATTAT

25 1601 TTTTGATGGC GTTAACTCGG CGTTTCATCT GTGGTGCAAC GGGCGCTGGG

1651 TCGGTTACGG CCAGGACAGT CGTTTGCCGT CTGAATTTGA CCTGAGCGCA

1701 TTTTACGCG CCGGAGAAAA CCGCCTCGCG GTGATGGTGC TCGGTTGGAG

30 1751 TGACGGCAGT TATCTGGAAG ATCAGGATAT GTGGCGGATG AGCGGCATTT

1801 TCCGTGACGT CTCGTTGCTG CATAAACCGA CTACACAAAT CAGCGATTTC

1851 CATGTTGCCA CTCGCTTTAA TGATGATTTC AGCCGCGCTG TACTGGAGGC

35 1901 TGAAGTTCAG ATGTGCGGCG AGTTGCGTGA CTACCTACGG GTAACAGTTT

1951 CTTTATGGCA GGGTGAAACG CAGGTCGCCA GCGGCACCGC GCCTTTCGGC

2001 GGTGAAATTA TCGATGAGCG TGGTGGTTAT GCCGATCGCG TCACACTACG

40 2051 TCTGAACGTC GAAAACCCGA AACTGTGGAG CGCCGAAATC CCGAATCTCT

2101 ATCGTGCGGT GGTGAACTG CACACGCCG ACGGCACGCT GATTGAAGCA

2151 GAAGCCTGCG ATGTCGGTTT CCGCGAGGTG CGGATTGAAA ATGGTCTGCT

45 2201 GCTGCTGAAC GGCAAGCCGT TGCTGATTCTG AGGCGTTAAC CGTCACGAGC

2251 ATCATCCTCT GCATGGTCAG GTCATGGATG AGCAGACGAT GGTGCAGGAT

50 2301 ATCCTGCTGA TGAAGCAGAA CAACTTTAAC GCCGTGCGCT GTTCGCATTA

2351 TCCGAACCAT CCGCTGTGGT ACACGCTGTG CGACCGCTAC GGCCTGTATG

55



Table 1 continued

5        2401 TGGTGGATGA AGCCAATATT GAAACCCACG GCATGGTGCC AATGAATCGT  
       2451 CTGACCGATG ATCCGCGCTG GCTACCGGCG ATGAGCGAAC GCGTAACGCG  
       2501 AATGGTGCAG CGCGATCGTA ATCACCCGAG TGTGATCATC TGGTCGCTGG  
 10       2551 GGAATGAATC AGGCCACGGC GCTAATCACG ACGCGCTGTA TCGCTGGATC  
       2601 AAATCTGTCTG ATCCTTCCCG CCCGGTGCAG TATGAAGGCG GCGGAGCCGA  
       2651 CACCACGGCC ACCGATATTA TTTGCCCCGAT GTACGCGCGC GTGGATGAAG  
 15       2701 ACCAGCCCTT CCCGGCTGTG CCGAAATGGT CCATCAAAAA ATGGCTTTCTG  
       2751 CTACCTGGAG AGACGCGCCC GCTGATCCTT TGCGAATACG CCCACGCGAT  
       2801 GGGTAACAGT CTTGGCGGTT TCGCTAAATA CTGGCAGGCG TTTCGTCAGT  
 20       2851 ATCCCCGTTT ACAGGGCGGC TTCGTCTGGG ACTGGGTGGA TCAGTCGCTG  
       2901 ATTAAATATG ATGAAAACGG CAACCCGTGG TCGGCTTACG GCGGTGATTT  
       2951 TGGCGATACG CCGAACGATC GCCAGTTCTG TATGAACGGT CTGGTCTTTG  
 25       3001 CCGACCGCAC GCCGCATCCA GCGCTGACGG AAGCAAAACA CCAGCAGCAG  
       3051 TTTTTCAGT TCCGTTTATC CGGGCAAACC ATCGAAGTGA CCAGCGAATA  
 30       3101 CCTGTTCCGT CATAGCGATA ACGAGCTCCT GCACTGGATG GTGGCGCTGG  
       3151 ATGGTAAGCC GCTGGCAAGC GGTGAAGTGC CTCTGGATGT CGCTCCACAA  
       3201 GGTAACAGT TGATTGAACT GCCTGAACTA CCGCAGCCGG AGAGCGCCGG  
 35       3251 GCAACTCTGG CTCACAGTAC GCGTAGTGCA ACCGAACGCG ACCGCATGGT  
       3301 CAGAAGCCGG GCACATCAGC GCCTGGCAGC AGTGGCGTCT GGCGGAAAAC  
       3351 CTCAGTGTGA CGCTCCCCGC CGCGTCCCAC GCCATCCCCG ATCTGACCAC  
 40       3401 CAGCGAAATG GATTTTTTGCA TCGAGCTGGG TAATAAGCGT TGGCAATTTA  
       3451 ACCGCCAGTC AGGCTTTCTT TCACAGATGT GGATTGGCGA TAAAAACAA  
       3501 CTGCTGACGC CGCTGCGCGA TCAGTTCACC CGTGCACCGC TGGATAACGA  
 45       3551 CATTGGCGTA AGTGAAGCGA CCCGCATTGA CCCTAACGCC TGGGTGGAAC  
       3601 GCTGGAAGGC GCGGGGCCAT TACCAGGCCG AAGCAGCGTT GTTGCAGTGC  
       3651 ACGGCAGATA CACTTGCTGA TGCGGTGCTG ATTACGACCG CTCACGCGTG  
 50       3701 GCAGCATCAG GGGAAAACCT TATTTATCAG CCGGAAAACC TACCGGATTG

55

Table 1 continued

5	3751	ATGGTAGTGG	TCAAATGGCG	ATTACCGTTG	ATGTTGAAGT	GGCGAGCGAT	
	3801	ACACCGCATC	CGGCGCGGAT	TGGCCTGAAC	TGCCAGCTGG	CGCAGGTAGC	
	3851	AGAGCGGGTA	AACTGGCTCG	GATTAGGGCC	GCAAGAAAAC	TATCCCGACC	
10	3901	GCCTTACTGC	CGCCTGTTTT	GACCGCTGGG	ATCTGCCATT	GTCAGACATG	
	3951	TATACCCCGT	ACGTCTTCCC	GAGCGAAAAC	GGTCTGCGCT	GCGGGACGCG	
	4001	CGAATTGAAT	TATGGCCAC	ACCAAGTGGCG	CGGCGACTTC	CAGTTCAACA	
15	4051	TCAGCCGCTA	CAGTCAACAG	CAACTGATGG	AAACCAGCCA	TCGCCATCTG	
	4101	CTGCACGCGG	AAGAAGGCAC	ATGGCTGAAT	ATCGACGGTT	TCCATATGGG	
							mutated EcoRI site
20	4151	GATTGGTGGC	GACGACTCCT	GGAGCCCGTC	AGTATCGGCG	NNNNNNCAGC	
							stop codon lac Z
	4201	TGAGCGCCGG	TCGCTACCAT	TACCAGTTGG	TCTGGTGTCA	AAAATAATAA	
25							start codon lac Y
	4251	TAACCGGGCA	GGCCATGTCT	GCCCCGATTT	CGCGTAAGGA	AATCCATTAT	
	4301	GTACTATTTA	AAAAACACAA	ACTTTTGGAT	GTTCCGTTTA	TTCTTTTTCT	
30	4351	TTTACTTTTT	TATCATGGGA	GCCTACTTCC	CGTTTTTCCC	GATTTGGCTA	
	4401	CATGACATCA	ACCATATCAG	CAAAAGTGAT	ACGGGTATTA	TTTTTGCCGC	
	4451	TATTTCTCTG	TTCTCGCTAT	TATTCCAACC	GCTGTTTGGT	CTGCTTTCTG	
35	4501	ACAAACTCGG	GCTGCGCAA	TACCTGCTGT	GGATTATTAC	CGGCATGTTA	
	4551	GTGATGTTTG	CGCCGTTCTT	TATTTTATC	TTCGGGCCAC	TGTTACAATA	
40	4601	CAACATTTTA	GTAGGATCGA	TTGTTGGTGG	TATTTATCTA	GGCTTTTGTT	
	4651	TTAACGCCGG	TGCGCCAGCA	GTAGAGGCAT	TTATTGAGAA	AGTCAGCCGT	
	4701	CGCAGTAATT	TCGAATTTGG	TCGCGCGCGG	ATGTTTGGCT	GTGTTGGCTG	
45	4751	GGCGCTGTGT	GCCTCGATTG	TCGGCATCAT	G TTCACCATC	AATAATCAGT	
	4801	TTGTTTTCTG	GCTGGGCTCT	GGCTGTGCAC	TCATCCTCGC	CGTTTTACTC	
	4851	TTTTTCGCCA	AAACGGATGC	GCCCTCTTCT	GCCACGGTTG	CCAATGCGGT	
50	4901	AGGTGCCAAC	CATTCGGCAT	TTAGCCTTAA	GCTGGCACTG	GAACTGTTCA	

55

Table 1 continued

5 4951 GACAGCCAAA ACTGTGGTTT TTGTCACTGT ATGTTATTGG CGTTTCCTGC  
 5001 ACCTACGATG TTTTGGACCA ACAGTTTGCT AATTTCTTTA CTTCGTTCTT  
 5051 TGCTACCGGT GAACAGGGTA CGCGGGTATT TGGCTACGTA ACGACAATGG  
 10 5101 GCGAATTACT TAACGCCTCG ATTATGTTCT TTGCGCCACT GATCATTAAAT  
 5151 CGCATCGGTG GGAAAAACGC CCTGCTGCTG GCTGGCACTA TTATGTCTGT  
 5201 ACGTATTATT GGCTCATCGT TCGCCACCTC AGCGCTGGAA GTGGTTATTC  
 15 5251 TGAAAACGCT GCATATGTTT GAAGTACCGT TCCTGCTGGT GGGCTGCTTT  
 5301 AAATATATTA CCAGCCAGTT TGAAGTGCCT TTTTCAGCGA CGATTTATCT  
 5351 GGTCTGTTTC TGCTTCTTTA AGCAACTGGC GATGATTTTT ATGTCTGTAC  
 20 5401 TGGCGGGCAA TATGTATGAA AGCATCGGTT TCCAGGGCGC TTATCTGGTG  
 5451 CTGGGTCTGG TGGCGCTGGG CTTCACCTTA ATTTCCGTGT TCACGCTTAG  
 25 5501 CGGCCCCGGC CCGCTTTCCT TGCTGCGTCG TCAGGTGAAT GAAGTCGCTT  
 5551 AAGCAATCAA TGTCGGATGC GGCGCGACGC TTATCCGACC AACATATCAT  
 30 5601 AACGGAGTGA TCGCATTGAA CATGCCAATG ACCGAAAGAA TAAGAGCAGG  
 5651 CAAGCTATTT ACCGATATGT GCGAAGGCTT ACCGGAAAAA AGACTTCGTG  
 5701 GGAAAACGTT AATGTATGAG TTTAATCACT CGCATCCATC AGAAGTTGAA  
 35 5751 AAAAGAGAAA GCCTGATTAA AGAAATGTTT GCCACGGTAG GGGAAAACGC  
 5801 CTGGGTAGAA CCGCCTGTCT ATTTCTCTTA CGGTTCCAAC ATCCATATAG  
 40 5851 GCCGCAATTT TTATGCAAAT TTCAATTTAA CCATTGTCGA TGA CTACACG  
 5901 GTAACAATCG GTGATAACGT ACTGATTGCA CCCAACGTTA CTCTTCCGT  
 5951 TACGGGACAC CCTGTACACC ATGAATTGAG AAAAAACGGC GAGATGTACT  
 45 6001 CTTTTCGGAT AACGATTGGC AATAACGTCT GGATCGGAAG TCATGTGGTT  
 6051 ATTAATCCAG GCGTCACCAT CGGGGATAAT TCTGTTATTG GCGCGGGTAG  
 6101 TATCGTCACA AAAGACATTC CACCAAACGT CGTGGCGGCT GGC GTTCCTT  
 50 6151 GTCGGGTAT TCGCGAAATA AACGACCGGG ATAAGCACTA TTATTTCAA

stop codon  
lac Y

start codon  
lac A

Table 1 continued

5				stop codon		
				lac A		
	6201	GATTATAAAG	TTGAATCGTC	AGTTTAAATT	ATAAAAATTG	CCTGATACGC
	6251	TGCGCTTATC	AGGCCTACAA	GTTTCAGCGAT	CTACATTAGC	CGCATCCGGC
10	6301	ATGAACAAAG	CGCAGGAACA	AGCGTCGCAT	CATGCCTCTT	TGACCCACAG
	6351	CTGCGGAAAA	CGTACTGGTG	CAAAACGCAG	GGTTATGATC	ATCAGCCCCA
	6401	CGACGCACAG	CGCATGAAAT	GCCAGTCCA	TCAGGTAATT	GCCGCTGATA
15	6451	CTACGCAGCA	CGCCAGAAAA	CCACGGGGCA	AGCCCGGCGA	TGATAAAACC
	6501	GATTCCCTGC	ATAAACGCCA	CCAGCTTGCC	AGCAATAGCC	GGTTGCACAG
	6551	AGTGATCGAG	CGCCAGCAGC	AAACAGAGCG	GAAACGCGCC	GCCCAGACCT
20	6601	AACCCACACA	CCATCGCCCA	CAATACCGGC	AATTGCATCG	GCAGCCAGAT
	6651	AAAGCCGCAG	AACCCACCA	GTTGTAACAC	CAGCGCCAGC	ATTAACAGTT
	6701	TGCGCCGATC	CTGATGGCGA	GCCATAGCAG	GCATCAGCAA	AGTCTCTGCG
25	6751	GCTTGCCCAA	GCGTCATCAA	TGCCAGTAAG	GAACCGCTGT	ACTGCGCGCT
	6801	GGCACCAATC	TCAATATAGA	AAGCGGGTAA	CCAGGCAATC	AGGCTGGCGT
	6851	AACCGCCGTT	AATCAGACCG	AAGTAAACAC	CCAGCGTCCA	CGCGCGGGGA
30	6901	GTGAATACCA	CGCGAACCGG	AGTGGTTGTT	GTCTTGTTGGG	AAGAGGCGAC
	6951	CTCGCGGGCG	CTTTGCCACC	ACCAGGCAAA	GAGCGCAACA	ACGGCAGGCA
	7001	GCGCCACCAG	GCGAGTGTTT	GATACCAGGT	TTCGCTATGT	TGAACTAACC
35	7051	AGGGCGTTAT	GGCGGCACCA	AGCCCAACCGC	CGCCCATCAG	AGCCGCGGAC
	7101	CACAGCCCCA	TCACCAGTGG	CGTGCGCTGC	TGAAACCGCC	GTTTAATCAC
	7151	CGAAGCATCA	CGCCTGAAT	GATGCCGATC	CCACCCCCAC	CAAGCAGTGC
	7201	GCTGCTAAGC	AGCAGCGCAC	TTTGCGGGTA	AAGCTCACGC	ATCAATGCAC
40	7251	CGACGGCAAT	CAGCAACAGA	CTGATGGCGA	CACTGCGACG	TTCGCTGACA
	7301	TGCTGATGAA	GCCAGCTTCC	GGCCAGCGCC	AGCCCGCCCA	TGGTAACCAC
				SalI site in pSKS107		
45	7351	CGGCAGAGCG	GTCGAC			

(1) sequence in bold, between the two ' marks, is synthetic DNA used to fuse the lac operon to the lac I or lac I<sup>q</sup> gene operon.

(2) pSKS107 contains an unsequenced mutation at the EcoRI site normally found in the lac Z gene.

Table 2.

Lactose Inducibility of Various Constructs			
Hours after <sup>(1)</sup> Induction	Lactose (mM)	Cells/ml	Toxin <sup>(2)</sup> (ug/ml)
<b>MR471</b>			
40	0	$1.6 \times 10^{10}$	none detected
40 no lactose	2 mM IPTG	$2.3 \times 10^{10}$	1003
15	20	$9.1 \times 10^9$	1011
24	20	$1.2 \times 10^{10}$	737
15	40	$1.8 \times 10^{10}$	887
24	40	$1.1 \times 10^{10}$	1025
23 <sup>(3)</sup>	8.3 <sup>(4)</sup>	$1.9 \times 10^{10}$	938
39 <sup>(3)</sup>	8.3 <sup>(4)</sup>	$2.0 \times 10^{10}$	1555
<b>MB101 containing pMYC485</b>			
24	40	-	775
24	0	-	none detected
<b>MB101 containing pMYC1161</b>			
24	40	-	300
24	0	-	none detected

(1) Cultures were induced upon reaching stationary phase.

(2) Toxin concentration was determined by laser densitometry of Coomassie-stained protein bands after electrophoresis of disrupted cells on SDS-PAGE (LKB Instructional Manual 2222-010).

(3) This experiment used MR471 grown in a 10L fermentor. All other experimental data were generated using same medium in 250 ml baffled shake flasks.

(4) In the fermentor, 8.3 mM lactose/hour was fed into the culture. It was found that MR471 did not metabolize this lactose level in a fermentor, resulting in increased concentrations during the experiment. The experiments done in shake flasks were given a single dose of lactose or IPTG at the indicated times.

#### 40 Claims

1. A modified lac operon, wherein the CAP binding site for catabolite repression and the promoter/operator are deleted, and wherein the lac I gene is fused to the ZY or ZYA gene, which substantially retains the parent operon's ability to control expression of a heterologous gene.
2. An operon according to claim 1, having the sequence shown in Table 1, or a mutation thereof.
3. A DNA construct comprising an operon according to claim 1 or claim 2 and also the heterologous gene.
4. A transfer vector, e.g. a plasmid, comprising an operon or DNA as defined in any preceding claim.
5. A microbial host transformed by the transfer vector of claim 4.
6. A process for preparing a polypeptide encoded by the heterologous gene, which comprises culturing a microbe comprising DNA as defined in claim 3.




Figure 1

PLASMIDMAP of: pMYC2005 check: 4484 from: 1 to: 2526




Figure 2





Figure 3

PLASMIDMAP of: pMYC467 check: 3500 from 1 to: 16100





### Figure 4

FLASHIDMAP of: PHYC471 check: 3500 from 1 to: 23500




Figure 5

FLASHIDMAP of: pMYC485 check: 3508 from: 1 to: 23500




Figure 6

FLASHIDMAP of: pMYC1161 check: 3500 from 1 to: 21900



European  
Patent Office

## EUROPEAN SEARCH REPORT

Application Number

EP 90 30 7952

### DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	GENES & DEVELOPMENT, vol. 1, no. 3, 1987, pages 227-237, New York, US; J.K. WHORISKEY et al.: "Genetic rearrangements and gene amplification in Escherichia coli: DNA sequences at the junctures of amplified gene fusions" * Abstract; page 228, column 2, line 26 - page 229, column 2, line 24; page 229, figure 3 * - - -	1,2	C 12 N 15/72 C 12 N 1/21
A	JOURNAL OF MOLECULAR BIOLOGY, vol. 186, no. 4, 1985, pages 733-742, London, GB; K.C. CONE et al.: "Functional analysis of lac repressor restart sites in translational initiation and reinitiation" * Abstract; page 735, column 1, line 40 - page 736, column 1, line 8; page 739, column 2, line 28 - page 740, column 1, line 13 * - - -	1,2	
A	NUCLEIC ACIDS RESEARCH, vol. 12, no. 13, 1984, pages 5449-5464, Oxford, GB; X.-M. YU et al.: "Deletion analysis of the CAP-cAMP binding site of the Escherichia coli lactose promoter" * Abstract; page 84, line 1 - page 85, line 5 * - - - - -	1	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C 12 N 15/00
Place of search		Date of completion of search	Examiner
The Hague		17 October 90	GURDJIAN D P M
CATEGORY OF CITED DOCUMENTS			
X: particularly relevant if taken alone		E: earlier patent document, but published on, or after the filing date	
Y: particularly relevant if combined with another document of the same category		D: document cited in the application	
A: technological background		L: document cited for other reasons	
O: non-written disclosure		-----	
P: intermediate document		&: member of the same patent family, corresponding document	
T: theory or principle underlying the invention			

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images  
problems checked, please do not report the  
problems to the IFW Image Problem Mailbox**

**THIS PAGE BLANK (USPTO)**